New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.
复制标题
DOI：
10.3389/fimmu.2017.01804
复制
发表时间：
2017
影响因子：
7.3
通讯作者：
Kremer L
中科院分区：
文献类型：
--
作者：
Corraliza-Gorjón I;Somovilla-Crespo B;Santamaria S;Garcia-Sanz JA;Kremer L
在过去的二十年中，抗体已经证明了其在抗肿瘤治疗中的高价值。它们目前被用作治疗一些最常见的转移性癌症的首选，如HER 2+乳腺癌或结直肠癌，目前分别用曲妥珠单抗（赫赛汀）和贝伐珠单抗（阿瓦斯丁）治疗。抑制免疫检查点的抗体的令人印象深刻的治疗成功已经将治疗性抗体的使用扩展到以前未预料到的肿瘤类型。这些抗免疫检查点抗体允许通过恢复患者自身对肿瘤的免疫反应来治愈缺乏其他治疗选择的患者。在这篇综述中，我们描述了基于抗体的治疗将如何发展，包括抗体组合的使用，它们的主要特征，优势，以及它们如何有助于显着增加癌症治疗成功的机会。实际上，新的组合将由针对相同分子的不同表位或相同肿瘤细胞上的不同靶标的抗体的混合物;能够同时结合肿瘤细胞、免疫细胞或细胞外分子的双特异性或多特异性抗体;免疫调节抗体;基于抗体的分子，包括配体或受体结构域与IgG Fab或Fc片段之间的融合蛋白;自体或异源细胞;以及不同形式的疫苗。通过互补的作用机制，这些组合可能有助于避免目前单一抗体仅识别一种特定表位的局限性。这些组合可以通过使用自身免疫细胞的帮助来同时攻击癌细胞，并基于更特异，快速和强大的反应发挥更广泛的治疗效果，试图模仿免疫系统的作用。
Antibodies have proven their high value in antitumor therapy over the last two decades. They are currently being used as the first-choice to treat some of the most frequent metastatic cancers, like HER2+ breast cancers or colorectal cancers, currently treated with trastuzumab (Herceptin) and bevacizumab (Avastin), respectively. The impressive therapeutic success of antibodies inhibiting immune checkpoints has extended the use of therapeutic antibodies to previously unanticipated tumor types. These anti-immune checkpoint antibodies allowed the cure of patients devoid of other therapeutic options, through the recovery of the patient’s own immune response against the tumor. In this review, we describe how the antibody-based therapies will evolve, including the use of antibodies in combinations, their main characteristics, advantages, and how they could contribute to significantly increase the chances of success in cancer therapy. Indeed, novel combinations will consist of mixtures of antibodies against either different epitopes of the same molecule or different targets on the same tumor cell; bispecific or multispecific antibodies able of simultaneously binding tumor cells, immune cells or extracellular molecules; immunomodulatory antibodies; antibody-based molecules, including fusion proteins between a ligand or a receptor domain and the IgG Fab or Fc fragments; autologous or heterologous cells; and different formats of vaccines. Through complementary mechanisms of action, these combinations could contribute to elude the current limitations of a single antibody which recognizes only one particular epitope. These combinations may allow the simultaneous attack of the cancer cells by using the help of the own immune cells and exerting wider therapeutic effects, based on a more specific, fast, and robust response, trying to mimic the action of the immune system.
登录
查看更多内容
影响因子：
11.5
作者：
Adkins, JC;Spencer, CM
通讯作者：
Spencer, CM
影响因子：
6.1
作者：
Ansell, Stephen M.
通讯作者：
Ansell, Stephen M.
影响因子：
2.4
作者：
Adler, Mark J.;Dimitrov, Dimiter S.
通讯作者：
Dimitrov, Dimiter S.
DOI：
10.1186/bcr3621
发表时间：
2014-03-05
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Barok M;Joensuu H;Isola J
通讯作者：
Isola J
影响因子：
7.2
作者：
Bacac M;Klein C;Umana P
通讯作者：
Umana P